Genmab A/S Sponsored ADR $GMAB Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp cut its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 1.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 41,425 shares of the company’s stock after selling 726 shares during the period. Fifth Third Bancorp’s holdings in Genmab A/S were worth $856,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Orbis Allan Gray Ltd grew its holdings in Genmab A/S by 102.8% during the first quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company’s stock worth $111,816,000 after acquiring an additional 2,895,179 shares during the period. Cubist Systematic Strategies LLC grew its holdings in Genmab A/S by 112.4% during the first quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after acquiring an additional 665,893 shares during the period. Russell Investments Group Ltd. grew its holdings in Genmab A/S by 111.5% during the first quarter. Russell Investments Group Ltd. now owns 1,080,129 shares of the company’s stock worth $21,149,000 after acquiring an additional 569,345 shares during the period. DDD Partners LLC grew its holdings in Genmab A/S by 165.9% during the first quarter. DDD Partners LLC now owns 601,050 shares of the company’s stock worth $11,769,000 after acquiring an additional 374,976 shares during the period. Finally, Eagle Global Advisors LLC acquired a new stake in Genmab A/S during the first quarter worth about $4,098,000. 7.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on GMAB shares. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a report on Friday. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 8th. Finally, HC Wainwright raised their target price on Genmab A/S from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and an average price target of $40.00.

Genmab A/S Trading Up 0.8%

Shares of GMAB opened at $29.07 on Monday. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $29.51. The stock’s 50 day moving average is $24.96 and its two-hundred day moving average is $22.07. The firm has a market cap of $18.65 billion, a P/E ratio of 14.61, a PEG ratio of 1.70 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.